HomeTWST • NASDAQ
add
Twist Bioscience Corp
Previous close
$49.06
Day range
$47.90 - $49.94
Year range
$23.30 - $51.00
Market cap
2.97B USD
Avg Volume
1.42M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 103.70M | 16.89% |
Operating expense | 86.87M | 12.12% |
Net income | -30.51M | 3.44% |
Net profit margin | -29.42 | 17.38% |
Earnings per share | -0.50 | 5.66% |
EBITDA | -27.01M | 5.45% |
Effective tax rate | -0.84% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 197.95M | -26.91% |
Total assets | 638.08M | 4.85% |
Total liabilities | 181.99M | 19.23% |
Total equity | 456.10M | — |
Shares outstanding | 61.31M | — |
Price to book | 6.59 | — |
Return on assets | -12.85% | — |
Return on capital | -14.52% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -30.51M | 3.44% |
Cash from operations | -24.81M | -15.80% |
Cash from investing | -9.93M | -546.68% |
Cash from financing | 298.00K | -98.34% |
Net change in cash | -34.44M | -578.89% |
Free cash flow | -25.86M | -130.04% |
About
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
Founded
2013
Website
Employees
979
